

Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-Jun-2020
Document Type: USP Monographs
DocId: GUID-587F7E50-3D3C-416C-BCD3-D8D19A737F29_5_en-US
DOI: https://doi.org/10.31003/USPNF_M81600_05_01
DOI Ref: bg418

© 2025 USPC
Do not distribute

Tetracaine Hydrochloride

$C_{15}H_{24}N_2O_2 \cdot HCl$ 300.82
Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester, monohydrochloride;
2-(Dimethylamino)ethyl *p*-(butylamino)benzoate monohydrochloride CAS RN®: 136-47-0; UNII: 5NF5D4OPCI.

DEFINITION
Tetracaine Hydrochloride contains NLT 98.0% and NMT 102.0% of tetracaine hydrochloride ($C_{15}H_{24}N_2O_2 \cdot HCl$), calculated on the anhydrous basis.

- IDENTIFICATION**
- **A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197K](#)**
 - **B. [IDENTIFICATION TESTS—GENERAL, Chloride \(191\)](#)**
Sample solution: 20 mg/mL
Acceptance criteria: Meets the requirements
 - **C.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

- **PROCEDURE**
Prepare the standard solutions and sample solutions immediately before use, or store them at a temperature of 2°–8°. Protect them from light.
Buffer: 1.36 g/L of monobasic potassium phosphate in water prepared as follows. Dissolve 1.36 g of monobasic potassium phosphate in about 600 mL water, and add 0.5 mL of phosphoric acid. Dilute with water to 1 L.
Mobile phase: See [Table 1](#).

Table 1

Time (min)	Buffer (%)	Acetonitrile (%)
0	80	20
3	80	20
18	40	60
23	40	60
23.1	80	20
28	80	20

Diluent: Acetonitrile and water (20:80)
Standard stock solution: 0.4 mg/mL of [USP Tetracaine Hydrochloride RS](#) in *Diluent*. Sonicate for 5 min.
Standard solution: 0.04 mg/mL of [USP Tetracaine Hydrochloride RS](#) from the *Standard stock solution* in *Diluent*
Sample stock solution: 0.4 mg/mL of Tetracaine Hydrochloride in *Diluent*. Sonicate for 5 min.
Sample solution: 0.04 mg/mL of Tetracaine Hydrochloride from the *Sample stock solution* in *Diluent*
Chromatographic system
(See [Chromatography \(621\)](#), [System Suitability](#).)
Mode: LC

Detector: UV 300 nm**Column:** 4.6-mm × 15-cm; 5-μm packing L1**Temperatures****Column:** 30°**Autosampler:** 4°**Flow rate:** 1.5 mL/min**Injection volume:** 10 μL**System suitability****Sample:** *Standard solution***Suitability requirements****Tailing factor:** NMT 1.5**Relative standard deviation:** NMT 0.73%**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of tetracaine hydrochloride ($C_{15}H_{24}N_2O_2 \cdot HCl$) in the portion of Tetracaine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* C_S = concentration of [USP Tetracaine Hydrochloride RS](#) in the *Standard solution* (mg/mL) C_U = concentration of Tetracaine Hydrochloride in the *Sample solution* (mg/mL)**Acceptance criteria:** 98.0%–102.0% on the anhydrous basis**IMPURITIES**

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

Change to read:

- **ORGANIC IMPURITIES**

Buffer, Mobile phase, Diluent, and Chromatographic system: Proceed as directed in the Assay.**Standard solution:** 0.004 mg/mL each of [USP Tetracaine Hydrochloride RS](#), [USP Tetracaine Related Compound B RS](#), [USP Tetracaine Related Compound C RS](#), and [USP Aminobenzoic Acid RS](#) in *Diluent***Sample solution:** 1 mg/mL of Tetracaine Hydrochloride in *Diluent***System suitability****Sample:** *Standard solution*[NOTE—See [Table 2](#) for the relative retention times.]**Suitability requirements****Resolution:** NLT 5.0 between tetracaine and tetracaine related compound B**Relative standard deviation:** NMT 5.0% for tetracaine hydrochloride**Analysis****Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of aminobenzoic acid, tetracaine related compound B, and tetracaine related compound C in the portion of Tetracaine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of corresponding tetracaine related compound from the *Sample solution* r_S = peak response of corresponding tetracaine related compound from the *Standard solution* C_S = concentration of corresponding tetracaine related compound in the *Standard solution* (mg/mL) C_U = concentration of Tetracaine Hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of each unspecified impurity in the portion of Tetracaine Hydrochloride taken:

r_U = peak response of each unspecified impurity from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Tetracaine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Tetracaine Hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). Disregard any impurity peaks less than 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Aminobenzoic acid ^a	0.3	0.4
Tetracaine hydrochloride	1	—
Tetracaine ▲▲ (ERR 1-Jun-2020) related compound B	1.7	0.4
Tetracaine ▲▲ (ERR 1-Jun-2020) related compound C	2.1	0.4
Individual unspecified impurity	—	0.4
Total impurities	—	0.8

^a 4-Aminobenzoic acid.

SPECIFIC TESTS

- [WATER DETERMINATION, Method I\(921\)](#): NMT 2.0%
- [STERILITY TESTS \(71\)](#): Where the label states that Tetracaine Hydrochloride is sterile, it meets the requirements.
- [BACTERIAL ENDOTOXINS TEST \(85\)](#): Where the label states that Tetracaine Hydrochloride is sterile or must be subjected to further processing during the preparation of injectable or other sterile dosage forms, it contains NMT 0.7 USP Endotoxin Units/mg of tetracaine hydrochloride.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.
- **LABELING:** Where it is intended for use in preparing injectable dosage forms, the label states that it is sterile or must be subjected to further processing during the preparation of injectable or other sterile dosage forms.
- [USP REFERENCE STANDARDS \(11\)](#).

[USP Aminobenzoic Acid RS](#)

[USP Tetracaine Hydrochloride RS](#)

[USP Tetracaine Related Compound B RS](#)

4-(Butylamino)benzoic acid.

$C_{11}H_{15}NO_2$ 193.24

[USP Tetracaine Related Compound C RS](#)

Methyl 4-(butylamino)benzoate.

$C_{12}H_{17}NO_2$ 207.35

Topic/Question	Contact	Expert Committee
TETRACAINE HYDROCHLORIDE	Documentary Standards Support	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(6)

Current DocID: GUID-587F7E50-3D3C-416C-BCD3-D8D19A737F29_5_en-US

DOI: https://doi.org/10.31003/USPNF_M81600_05_01

DOI ref: [bg418](#)

OFFICIAL